Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Medications: Interactions with Diet, Herbs, Dietary Supplements and Probiotics
share announcement

Medications: Interactions with Diet, Herbs, Dietary Supplements and Probiotics

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 2319

Special Issue Editors

Dr. Francisco Rivas

E-Mail Website
Guest Editor
Municipal Health and Consumer Unit, Guadix City Council (Granada), School of Health Sciences, Valencia International University, Valencia, Spain
Interests: bioethics; parenteral nutrition; health education; pharmacy
Special Issues, Collections and Topics in MDPI journals
Dr. María Isabel Valverde Merino

E-Mail Website1 Website2 Website3
Guest Editor
Pharmaceutical Care Research Group, University of Granada, Granada, Spain
Interests: pharmaceutical care; nutritional sciences; health education; pharmacy education; social pharmacy; community pharmacy services
Dr. Maria José Zarzuelo Romero

E-Mail Website1 Website2
Guest Editor
Faculty of Pharmacy, University of Granada, Granada, Spain
Interests: pharmaceutical care; health education; pharmacy education; social pharmacy

Special Issue Information

Dear Colleagues,

The optimal result of any pharmacological treatment depends on a variety of factors. However, one that has recently received significant attention due to its importance concerns the interactions that can occur between medications, foods and dietary supplements. These interactions can lead to an increase or a decrease in the plasma concentration of the drug; therefore, in both cases, health may be affected either due to possible toxicity or the absence of therapeutic action.

The objective of this Special Issue is to update the available scientific and clinically relevant evidence on the main interactions that can occur, exploring how healthcare professionals can intervene to prevent them and thus guarantee the optimization of pharmacological treatment while reducing healthcare costs associated with morbidity and mortality.

Dr. Francisco Rivas
Dr. María Isabel Valverde Merino
Dr. Maria José Zarzuelo Romero
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • food–drug interactions
  • dietary supplements
  • probiotics
  • herb–drug interaction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 11171 KiB  
Article
Quinazolinone Derivative MR2938 Protects DSS-Induced Barrier Dysfunction in Mice Through Regulating Gut Microbiota
by Ling Lv, Mireguli Maimaitiming, Jichen Yang, Shuli Xia, Xin Li, Pingyuan Wang, Zhiqing Liu and Chang-Yun Wang
Pharmaceuticals 2025, 18(1), 123; https://doi.org/10.3390/ph18010123 - 17 Jan 2025
Viewed by 547
Abstract
Background/Objectives: Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by colorectal immune infiltration and significant microbiota compositional changes. Gut microbiota homeostasis is necessary to maintain the healthy state of humans. MR2938, a quinazolin-4(3H)-one derivative derived from the marine natural [...] Read more.
Background/Objectives: Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by colorectal immune infiltration and significant microbiota compositional changes. Gut microbiota homeostasis is necessary to maintain the healthy state of humans. MR2938, a quinazolin-4(3H)-one derivative derived from the marine natural product penipanoid C, alleviated DSS-induced colitis in a dose-dependent manner. Herein, we aimed to investigate the impact of MR2938 on the gut microbiota in dextran sodium sulfate (DSS)-induced colitis in mice and to elucidate the role of the gut microbiota in the therapeutic mechanism of MR2938 for alleviating colitis. Methods: Acute colitis was induced with DSS in mice. Mice were administered with 100 mg/kg or 50 mg/kg of MR2938. Cecal content was also preserved in liquid nitrogen and subsequently analyzed following 16S RNA sequencing. Antibiotic cocktail-induced microbiome depletion was performed to further investigate the relationship between MR2938 and gut microbiota. The inflammatory factor levels were performed by quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA). Alcian blue staining and immunofluorescence were used to estimate the intestinal barrier. Results: The 16S rRNA sequencing revealed microbiota modulation by MR2938. Compared with the model group, the 100 mg/kg MR2938 group was associated with higher abundances of Entercoccus and a lower abundance of Staphylococcus, while the 50 mg/kg MR2938 group was associated with higher abundances of Lactobacillus and a lower abundance of Staphylococcus. The antibiotic-mediated microbiota depletion experiments demonstrated that the gut microbiota primarily contributed to barrier function protection, with little impact on inflammatory factor levels during the MR2938 treatment. Conclusions: These findings suggest that intestinal flora play a crucial role in MR2938’s therapeutic mechanism for alleviating colitis. Full article
(This article belongs to the Special Issue Medications: Interactions with Diet, Herbs, Dietary Supplements and Probiotics)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 785 KiB  
Review
Dietary Supplements for Weight Loss and Drug Interactions
by Francisco Rivas García, José Antonio García Sierra, Maria-Isabel Valverde-Merino and Maria Jose Zarzuelo Romero
Pharmaceuticals 2024, 17(12), 1658; https://doi.org/10.3390/ph17121658 - 9 Dec 2024
Viewed by 1191
Abstract
Food supplements are used for a variety of purposes, one of which is weight reduction. As excess weight is a long-term condition, some supplements are expected to be used for long periods of time. The long-term use of these dietary supplements makes it [...] Read more.
Food supplements are used for a variety of purposes, one of which is weight reduction. As excess weight is a long-term condition, some supplements are expected to be used for long periods of time. The long-term use of these dietary supplements makes it highly likely that they will be combined with medications, increasing the risk of food supplement–drug interactions, which are not always known or disclosed, and can lead to serious health problems, as has been observed. This article discusses some of the compounds used as food supplements for weight reduction (green tea extract, Garcinia cambogia, chitosan, quercetin and resveratrol) and the interactions they may cause with some drugs such as: dextromethorphan, buspirone, diclofenac, irinotecan, 5-fluorouracil, cytochrome P450 inducers and inhibitors, statins, orlistat, warfarina, acenocoumarol, fluoxetine, valproate, quetiapine, carbamazepine. This information is expected to be useful for healthcare professionals to detect and intervene on food supplement–drug interactions to ensure the optimization of therapy and patient safety. Full article
(This article belongs to the Special Issue Medications: Interactions with Diet, Herbs, Dietary Supplements and Probiotics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop